Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study
Authors:
- 13 December 2023
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 23 (1) , 60-70
Abstract
No abstract availableKeywords
Funding Information
- BioMarin Pharmaceutical
This publication has 21 references indexed in Scilit:
- Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseNew England Journal of Medicine, 2018
- Drug Hypersensitivity and Desensitizations: Mechanisms and New ApproachesInternational Journal of Molecular Sciences, 2017
- Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosisMolecular Genetics and Metabolism, 2016
- Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease ProgressionAmerican Journal of Neuroradiology, 2016
- OP48 – 2893: The DEM-CHILD NCL Patient Database: A tool for the evaluation of therapies in neuronal ceroid lipofuscinoses (NCL)European Journal of Paediatric Neurology, 2015
- NCL diseases — clinical perspectivesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Diagnosis and management of drug hypersensitivity reactionsJournal of Allergy and Clinical Immunology, 2011
- Neurological deterioration in late infantile neuronal ceroid lipofuscinosisNeurology, 2007
- Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutationsAmerican Journal of Medical Genetics, 2002
- Mutational Analysis of the Defective Protease in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis, a Neurodegenerative Lysosomal Storage DisorderThe American Journal of Human Genetics, 1999